Eli Lilly has filed a civil lawsuit alleging a $200 million rebate fraud scheme involving several bishops of the Church of God in Christ and a Florida mail-order pharmacy, DrugPlace. The scheme involved false claims for rebates on the diabetes drug Trulicity, with DrugPlace selling the drug on the secondary market while collecting fraudulent rebates. The lawsuit claims many patients tied to the claims did not exist or could not be verified, and the church itself is not named as a defendant. Lilly is seeking legal action to stop the fraud and protect access to its medicines.
Eli Lilly reported a 55.5% revenue increase in Q1 2026, driven by strong sales of Mounjaro and Zepbound. Despite this growth and raised full-year guidance, shares have fallen due to pricing pressures from China and the U.S., and competition from Novo...
Eli Lilly's next-generation obesity drug, retatrutide, achieved significant weight loss in a late-stage trial, with patients losing up to 28.3% of their body weight over 80 weeks. The drug, which targets three gut hormones, outperformed existing trea...
Incyte has signed a $120 million partnership with Genesis Molecular AI, including $80 million upfront and a $40 million equity investment, to advance AI-driven drug discovery. This deal could exceed $1 billion with future milestones and royalties, us...
The iShares U.S. Pharmaceuticals ETF (IHE) has gained 38% over the past year despite threats from U.S. drug pricing policies like the 'most favored nation' order. The ETF benefits from dividends and strong drug pipelines, especially from major holdin...
The Fidelity MSCI Health Care Index ETF (FHLC) has declined about 5% year-to-date, while the S&P 500 has risen 7%, and over five years FHLC returned 15% versus 80% for the S&P 500. FHLC tracks a broad healthcare index with 342 holdings but is heavily...
